Robert J. Ferdon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Robert J. Ferdon has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Jason Silvestre
Medical University of South Carolina, Charleston, USA
6 shared publications - Charles A. Reitman
Medical University of South Carolina, Charleston, USA
4 shared publications Robert A. Ravinsky
3 shared publications- James Lawrence
Department of Orthopaedics and Physical Medicine, Medical University of South Carolina, Charleston, SC
2 shared publications James P. Lawrence
Medical University of South Carolina, Charleston, US
2 shared publicationsJohn C. Martin
Medical University of South Carolina, Charleston, US
2 shared publications
Latest Publications
- 5 November 2026
- Published by Elsevier in Neurochirurgie
- Vol. 73 (1)
Impact of rigid postoperative bracing on outcomes following anterior cervical discectomy and fusion: A multi-institutional, propensity-matched cohort study
- 5 November 2026
- Published by Elsevier in Neurochirurgie
- Vol. 73 (1)
Impact of rigid postoperative bracing on outcomes following anterior cervical discectomy and fusion: A multi-institutional, propensity-matched cohort study
- Open Access
- 16 March 2026
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
- Vol. 20 (3) , 585-603
Recurrent lumbar disc herniation: a systematic review and meta-analysis of risk factors, surgical timing, and outcomes of revision discectomy versus fusion
Recurrent lumbar disc herniation (RLDH) occurs in up to 15% of patients after primary discectomy and poses challenges in surgical decision-making. Both revision discectomy (RD) and spinal fusion (SF) is utilized for reoperation, but the optimal treatment strategy remains a topic of debate. Additionally, data on the ideal timing for reoperation are limited. This study systematically reviewed risk factors for RLDH, evaluated surgical timing, and compared outcomes between RD and SF. A systematic review and meta-analysis were conducted following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines (PROSPERO-registered). The PubMed, Scopus, and CINAHL databases were searched through December 2024. Eligible studies included patients undergoing revision surgery for RLDH, with data on surgical technique, timing, and outcomes. The risk of bias was assessed using ROB-2 for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies. Random-effects meta-analysis was employed to pool 12-month improvements in Visual Analog Scale (VAS) back, VAS leg, and Oswestry Disability Index (ODI) scores. Additional outcomes included perioperative metrics, complications, recurrence rates, and patient satisfaction. Ten studies (including 939 patients) met the inclusion criteria. Reported risk factors included male sex, obesity, smoking, diabetes, and large annular defects. Surgical timing was inconsistently reported, which limited the pooled analysis. SF was associated with significantly greater intraoperative blood loss ((p=0.039), while operative time and hospitalization duration did not differ significantly. Recurrence rates did not significantly differ ((p=0.262), although open fusion showed a trend toward reduced recurrence. No significant differences in 12-month VAS or ODI scores were found between the groups (p>0.3). Minimally invasive techniques (minimally invasive transforaminal lumbar interbody fusion and percutaneous endoscopic lumbar discectomy) were associated with fewer complications and greater patient satisfaction. Both RD and SF are viable options for RLDH, each presenting distinct risk-benefit profiles. Importantly, this study highlights the inconsistent reporting of surgical timing as a persistent knowledge gap. Further high-quality research utilizing standardized definitions of recurrence and reoperation timeframes, with long-term follow-up, is necessary to clarify optimal surgical timing and guide treatment selection (PROSPERO CRD42024570791).
- 16 March 2026
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
- Vol. 20 (3) , 585-603
Open AccessRecurrent lumbar disc herniation: a systematic review and meta-analysis of risk factors, surgical timing, and outcomes of revision discectomy versus fusion
Recurrent lumbar disc herniation (RLDH) occurs in up to 15% of patients after primary discectomy and poses challenges in surgical decision-making. Both revision discectomy (RD) and spinal fusion (SF) is utilized for reoperation, but the optimal treatment strategy remains a topic of debate. Additionally, data on the ideal timing for reoperation are limited. This study systematically reviewed risk factors for RLDH, evaluated surgical timing, and compared outcomes between RD and SF. A systematic review and meta-analysis were conducted following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines (PROSPERO-registered). The PubMed, Scopus, and CINAHL databases were searched through December 2024. Eligible studies included patients undergoing revision surgery for RLDH, with data on surgical technique, timing, and outcomes. The risk of bias was assessed using ROB-2 for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies. Random-effects meta-analysis was employed to pool 12-month improvements in Visual Analog Scale (VAS) back, VAS leg, and Oswestry Disability Index (ODI) scores. Additional outcomes included perioperative metrics, complications, recurrence rates, and patient satisfaction. Ten studies (including 939 patients) met the inclusion criteria. Reported risk factors included male sex, obesity, smoking, diabetes, and large annular defects. Surgical timing was inconsistently reported, which limited the pooled analysis. SF was associated with significantly greater intraoperative blood loss ((p=0.039), while operative time and hospitalization duration did not differ significantly. Recurrence rates did not significantly differ ((p=0.262), although open fusion showed a trend toward reduced recurrence. No significant differences in 12-month VAS or ODI scores were found between the groups (p>0.3). Minimally invasive techniques (minimally invasive transforaminal lumbar interbody fusion and percutaneous endoscopic lumbar discectomy) were associated with fewer complications and greater patient satisfaction. Both RD and SF are viable options for RLDH, each presenting distinct risk-benefit profiles. Importantly, this study highlights the inconsistent reporting of surgical timing as a persistent knowledge gap. Further high-quality research utilizing standardized definitions of recurrence and reoperation timeframes, with long-term follow-up, is necessary to clarify optimal surgical timing and guide treatment selection (PROSPERO CRD42024570791).
- Open Access
- 6 January 2026
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
- Vol. 20 (3) , 442-454
Association of glucagon-like peptide-1 agonist therapy with postsurgical outcomes following multilevel correction for adult spinal deformity: a propensity score-matched analysis
Study Design: Retrospective cohort study. Purpose: This study aimed to examine outcomes in patients with adult spinal deformity (ASD) undergoing deformity correction with and without glucagon-like peptide-1 receptor agonist (GLP-1A) therapy. Overview of Literature: GLP-1As, widely used in diabetes management, have recently been linked to reduced postoperative complications. However, their role in spinal surgery remains underexplored. Methods: This multicenter, retrospective cohort study was conducted using the TriNetX Global Collaborative Database (2005-2025) utilizing Current Procedural Terminology and International Classification of Diseases, 10th Revision, codes for patients undergoing spinal deformity correction because of ASD. Patients prescribed GLP-1As within 1 year of surgery were 1:1 propensity-score matched with those who were not using GLP-1As. The cohort was matched according to patient demographics and comorbidities. Surgical outcomes between groups were analyzed at 1-and 2-year intervals. Significance was defined as p<0.05. Results: At 1 and 2 years following surgery, patients taking GLP-1As exhibited significantly lower odds of pseudoarthrosis, hardware failures, wound dehiscence, infections, thromboembolic events, readmissions, and mortality. Conclusions: The findings reveal a significant reduction in the rates of pseudoarthrosis, hardware failure, readmission, and mortality in patients treated with GLP-1As. These results align with the recent literature, pointing to a potential complementary therapy in ASD management. Further studies characterizing the mechanism by which GLP-1As affect postoperative spinal physiology are warranted to assess their utility in optimizing patient outcomes.
- 6 January 2026
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
- Vol. 20 (3) , 442-454
Open AccessAssociation of glucagon-like peptide-1 agonist therapy with postsurgical outcomes following multilevel correction for adult spinal deformity: a propensity score-matched analysis
Study Design: Retrospective cohort study. Purpose: This study aimed to examine outcomes in patients with adult spinal deformity (ASD) undergoing deformity correction with and without glucagon-like peptide-1 receptor agonist (GLP-1A) therapy. Overview of Literature: GLP-1As, widely used in diabetes management, have recently been linked to reduced postoperative complications. However, their role in spinal surgery remains underexplored. Methods: This multicenter, retrospective cohort study was conducted using the TriNetX Global Collaborative Database (2005-2025) utilizing Current Procedural Terminology and International Classification of Diseases, 10th Revision, codes for patients undergoing spinal deformity correction because of ASD. Patients prescribed GLP-1As within 1 year of surgery were 1:1 propensity-score matched with those who were not using GLP-1As. The cohort was matched according to patient demographics and comorbidities. Surgical outcomes between groups were analyzed at 1-and 2-year intervals. Significance was defined as p<0.05. Results: At 1 and 2 years following surgery, patients taking GLP-1As exhibited significantly lower odds of pseudoarthrosis, hardware failures, wound dehiscence, infections, thromboembolic events, readmissions, and mortality. Conclusions: The findings reveal a significant reduction in the rates of pseudoarthrosis, hardware failure, readmission, and mortality in patients treated with GLP-1As. These results align with the recent literature, pointing to a potential complementary therapy in ASD management. Further studies characterizing the mechanism by which GLP-1As affect postoperative spinal physiology are warranted to assess their utility in optimizing patient outcomes.
- Open Access
- 31 December 2025
- Published by Elsevier in North American Spine Society Journal (NASSJ)
- Vol. 25, 100845
Portal message utilization in orthopedic spine surgery: patterns, predictors, and financial implications
- 31 December 2025
- Published by Elsevier in North American Spine Society Journal (NASSJ)
- Vol. 25, 100845
Open AccessPortal message utilization in orthopedic spine surgery: patterns, predictors, and financial implications
- Open Access
- 24 December 2025
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 5 (4)
Preoperative antibiotic sensitivity testing for total joint replacement
- 24 December 2025
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 5 (4)
Open AccessPreoperative antibiotic sensitivity testing for total joint replacement
- 9 December 2025
- Published by Springer Nature in Spinal Cord
- Vol. 64 (1) , 71-78
Spinal cord injury research and national institutes of health funding: a call to action
Study design Cross-sectional study. Objectives The magnitude and nature of National Institutes of Health (NIH) funding for spinal cord injury (SCI) research is poorly characterized. This study elucidates the portfolio of NIH grants awarded for SCI research. Setting N/A Methods Data on NIH grants awarded for SCI research were extracted from the NIH RePORTER database (2013–2023). NIH funding was analyzed for twenty-five clinical areas and compound annual growth rates (CAGRs) were calculated over the study period. Results From 2013–2023, the NIH extramural research budget increased from $28.3 to $45.0 billion (CAGR 4.7%). A total of $986 million was awarded for SCI research, which increased from $93.6 to $97.7 million over the study period (CAGR 0.4%). Among the twenty-five clinical areas, dementia ($21.8 billion, CAGR 18.7%) and diabetes ($20.6 billion, CAGR 21.5%) had the most NIH funding. For SCI research, most NIH funding was awarded by the National Institute of Neurological Disorders and Stroke (67%) via the R01 (57%) grant mechanism. The clinical areas receiving the most NIH funding for SCI research were disease mechanisms (47%), prosthetics (22%), biologic therapies (18%), and pharmacologic therapies (6%). Several principal investigator characteristics were associated with higher NIH funding totals for SCI research including male (P < 0.001), full professor (P < 0.001), and MD, PhD degree (P = 0.044). Conclusions Growth in the annual NIH budget for SCI research has not kept pace with growth in the overall NIH extramural research budget. Future strategies are needed to support PIs in obtaining NIH grant funding for SCI research.
- 9 December 2025
- Published by Springer Nature in Spinal Cord
- Vol. 64 (1) , 71-78
Spinal cord injury research and national institutes of health funding: a call to action
Study design Cross-sectional study. Objectives The magnitude and nature of National Institutes of Health (NIH) funding for spinal cord injury (SCI) research is poorly characterized. This study elucidates the portfolio of NIH grants awarded for SCI research. Setting N/A Methods Data on NIH grants awarded for SCI research were extracted from the NIH RePORTER database (2013–2023). NIH funding was analyzed for twenty-five clinical areas and compound annual growth rates (CAGRs) were calculated over the study period. Results From 2013–2023, the NIH extramural research budget increased from $28.3 to $45.0 billion (CAGR 4.7%). A total of $986 million was awarded for SCI research, which increased from $93.6 to $97.7 million over the study period (CAGR 0.4%). Among the twenty-five clinical areas, dementia ($21.8 billion, CAGR 18.7%) and diabetes ($20.6 billion, CAGR 21.5%) had the most NIH funding. For SCI research, most NIH funding was awarded by the National Institute of Neurological Disorders and Stroke (67%) via the R01 (57%) grant mechanism. The clinical areas receiving the most NIH funding for SCI research were disease mechanisms (47%), prosthetics (22%), biologic therapies (18%), and pharmacologic therapies (6%). Several principal investigator characteristics were associated with higher NIH funding totals for SCI research including male (P < 0.001), full professor (P < 0.001), and MD, PhD degree (P = 0.044). Conclusions Growth in the annual NIH budget for SCI research has not kept pace with growth in the overall NIH extramural research budget. Future strategies are needed to support PIs in obtaining NIH grant funding for SCI research.
- Open Access
- 6 December 2025
- Published by Elsevier in North American Spine Society Journal (NASSJ)
- Vol. 25, 100832
Analysis of National Institutes of Health funding for back pain research in the United States
- 6 December 2025
- Published by Elsevier in North American Spine Society Journal (NASSJ)
- Vol. 25, 100832
Open AccessAnalysis of National Institutes of Health funding for back pain research in the United States